Gossamer Bio Förvaltning
Förvaltning kriterier kontrolleras 2/4
Gossamer Bio VD är Faheem Hasnain, utsedd i Nov 2020, har en mandatperiod på 5.42 år. totala årliga ersättningen är $ 2.30M, bestående av 28.2% lön 71.8% bonusar, inklusive företagsaktier och optioner. äger direkt 2.66% av företagets aktier, värda $ 2.15M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4.7 år respektive 4.8 år.
Viktig information
Faheem Hasnain
Verkställande direktör
US$2.3m
Total ersättning
| VD-lön i procent | 28.24% |
| Anställning som VD | 5.4yrs |
| Ägande av VD | 2.7% |
| Ledningens genomsnittliga anställningstid | 4.7yrs |
| Styrelsens genomsnittliga mandatperiod | 4.8yrs |
Senaste uppdateringar av ledningen
Recent updates
GOSS: Upcoming FDA Meeting Will Determine Potential Rerating After Phase 3 Setback
Analysts have lowered their average price targets on Gossamer Bio into the low single-digit dollar range, reflecting reduced modeled revenue growth, a higher discount rate, and increased regulatory uncertainty around seralutinib following the recent Phase 3 PROSERA miss and multiple rating downgrades. Analyst Commentary Recent Street research around Gossamer Bio clusters around two themes: how to weigh the mixed seralutinib data against the regulatory risk, and how to factor balance sheet constraints into valuation.
GOSS: Regulatory Path And Funding Outlook Will Shape Future Repricing Potential
Narrative Update: Gossamer Bio The average analyst price target for Gossamer Bio has moved sharply lower into the low single digits, with firms citing reduced probabilities of success for seralutinib in pulmonary arterial hypertension, a mixed Phase 3 PROSERA outcome that missed its primary endpoint, and added regulatory and funding uncertainty as key drivers behind the reset. Analyst Commentary Recent Street research around Gossamer Bio has turned more cautious, with several bearish analysts reacting to the Phase 3 PROSERA miss, regulatory uncertainty for seralutinib in pulmonary arterial hypertension, and funding needs.
GOSS: Regulatory Meetings On Phase 3 Miss Will Drive Future Rerating Potential
Narrative Update The analyst price target for Gossamer Bio has been reduced, with fair value moving from $15.00 to about $13.43 as analysts factor in a lower assumed probability of success for seralutinib in pulmonary arterial hypertension, heightened regulatory uncertainty after the Phase 3 PROSERA miss, and balance sheet concerns. These factors are partially offset by ongoing expectations for higher revenue growth, stronger profit margins, and a lower future P/E multiple.GOSS: Upcoming FDA Meeting And 2026 Data Readouts Will Drive Rerating Potential
Analysts have sharply reduced their average price targets on Gossamer Bio, cutting them from a prior fair value indication of about $9.50 to roughly $3.69. This change reflects reduced confidence in seralutinib's regulatory path and a reevaluation of risk after the PROSERA Phase 3 miss.GOSS: Index Additions And Barclays Bullish Coverage Will Support Future Repricing
Analysts have raised their price target on Gossamer Bio to $6.00, citing new bullish coverage that outlines the company’s updated assumptions for risk, growth, margins and future P/E, while maintaining their fair value estimate at $6.00. Analyst Commentary While the updated price target of US$6.00 reflects a constructive view on Gossamer Bio, some research commentary also highlights areas where expectations could be tested.GOSS: Index Additions And Bullish Research Coverage Will Support Future Repricing
Analysts have adjusted their price target for Gossamer Bio to US$6.00, with the updated view supported by slightly revised assumptions on discount rate, revenue growth, profit margin and future P/E following fresh bullish Street research coverage. Analyst Commentary While the updated US$6.00 price target reflects constructive views in recent research, not all commentators are aligned with the bullish tone.GOSS: Index Additions And February 2026 Data Will Drive Rerating Potential
Analysts have maintained their fair value estimate for Gossamer Bio at US$9.50 per share. They explained that only modest adjustments to assumptions such as the discount rate and future P/E were required, and these did not affect their overall price target view.Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27%
Jan 22
GOSS: Index Additions And Updated Assumptions Will Support Bullish Repricing
Analysts have revised their price target on Gossamer Bio to US$6.00, with the unchanged fair value level tied to updated assumptions that include adjusted discount rates, a higher modeled revenue growth rate of 59.16% and a lower future P/E of about 63.33x. These factors together shape their latest view of the share price outlook.Gossamer Bio: High-Risk Binary Approaches
Dec 19GOSS: Upcoming Respiratory Congress Data Will Likely Drive Stronger Market Reassessment
Analysts have sharply raised their price target on Gossamer Bio, with fair value estimates climbing from approximately 1.25 to 6.00 per share. They cite expectations for significantly faster revenue growth and a higher future earnings multiple, despite a modest uptick in discount rates and slightly lower projected profit margins.GOSS: Improving Market Conviction Will Drive Momentum Into February 2026 Data Release
Analysts have maintained their price target for Gossamer Bio at $9.50 per share, citing increasingly positive sentiment and renewed conviction about seralutinib’s outlook as key clinical milestones approach. Analyst Commentary As key clinical milestones for seralutinib approach, analysts have weighed in with both optimistic and cautious perspectives regarding Gossamer Bio’s future prospects and current valuation.Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up
Nov 25GOSS: Improving Sentiment Will Drive Momentum Ahead of February 2026 Data Readout
Analysts have raised their price target for Gossamer Bio from $8.86 to $9.50. They cite increased conviction in the company's upcoming clinical data and improving market sentiment around its lead drug candidate.Gossamer Bio, Inc. (NASDAQ:GOSS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Oct 11Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Analysts have raised their price target for Gossamer Bio from $7.75 to $8.86, citing optimism for seralutinib's novel mechanism and market potential in pulmonary hypertension as key drivers. Analyst Commentary Positive outlook on Gossamer Bio's strategy in targeting pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%
Aug 22Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Feb 14Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Sep 10Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Aug 14Peaking Back In On Gossamer Bio
Sep 27Gossamer Bio to raise $120M in a private equity placement
Jul 13Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Sep 22Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
Jan 28Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$650k | -US$170m |
| Sep 30 2025 | n/a | n/a | -US$156m |
| Jun 30 2025 | n/a | n/a | -US$139m |
| Mar 31 2025 | n/a | n/a | -US$51m |
| Dec 31 2024 | US$2m | US$628k | -US$57m |
| Sep 30 2024 | n/a | n/a | -US$72m |
| Jun 30 2024 | n/a | n/a | -US$81m |
| Mar 31 2024 | n/a | n/a | -US$173m |
| Dec 31 2023 | US$2m | US$607k | -US$180m |
| Sep 30 2023 | n/a | n/a | -US$187m |
| Jun 30 2023 | n/a | n/a | -US$207m |
| Mar 31 2023 | n/a | n/a | -US$221m |
| Dec 31 2022 | US$7m | US$592k | -US$229m |
| Sep 30 2022 | n/a | n/a | -US$230m |
| Jun 30 2022 | n/a | n/a | -US$231m |
| Mar 31 2022 | n/a | n/a | -US$234m |
| Dec 31 2021 | US$5m | US$574k | -US$234m |
| Sep 30 2021 | n/a | n/a | -US$242m |
| Jun 30 2021 | n/a | n/a | -US$240m |
| Mar 31 2021 | n/a | n/a | -US$247m |
| Dec 31 2020 | US$1m | US$72k | -US$243m |
| Sep 30 2020 | n/a | n/a | -US$233m |
| Jun 30 2020 | n/a | n/a | -US$224m |
| Mar 31 2020 | n/a | n/a | -US$202m |
| Dec 31 2019 | US$1m | US$200k | -US$180m |
Ersättning vs marknad: Faheem s total kompensation ($USD 2.30M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 621.84K ).
Ersättning vs inkomst: Ersättningen för Faheem har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Faheem Hasnain (67 yo)
5.4yrs
Anställning
US$2,300,455
Kompensation
Mr. Faheem Hasnain is Chairman of the Board of Sling Therapeutics, Inc. He has been Chief Executive Officer and President at Gossamer Bio, Inc. since November 16, 2020. He served as Executive Advisor at Ve...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 5.4yrs | US$2.30m | 2.66% $ 2.1m | |
| COO & CFO | 7.9yrs | US$1.25m | 0.32% $ 259.3k | |
| Chief Commercial Officer | 2.3yrs | US$1.18m | inga uppgifter | |
| Executive Vice President of Technical Operations & Administration | 4.1yrs | US$1.65m | 0.34% $ 274.3k | |
| General Counsel & Secretary | 5.3yrs | inga uppgifter | inga uppgifter | |
| Senior Vice President of Marketing | 1.2yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Human Resources | no data | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | no data | US$1.07m | 0.089% $ 72.0k | |
| Senior Vice President of Clinical Development of Pulmonary Vascular Disease | 1.6yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Regulatory Affairs | 8yrs | inga uppgifter | 0.11% $ 89.2k | |
| Senior Vice President of Biometrics | 5.1yrs | inga uppgifter | inga uppgifter | |
| MD & President of Gossamer Bio Ireland | 4.3yrs | inga uppgifter | inga uppgifter |
4.7yrs
Genomsnittlig anställningstid
61yo
Genomsnittlig ålder
Erfaren ledning: GOSS s ledningsgrupp anses vara erfaren ( 4.7 års genomsnittlig anställningstid).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 10.5yrs | US$2.30m | 2.66% $ 2.1m | |
| Independent Director | 7.4yrs | US$186.32k | 0.0031% $ 2.5k | |
| Lead Independent Director | 8.3yrs | US$199.57k | 0.016% $ 13.1k | |
| Independent Director | 2.4yrs | US$172.07k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$179.32k | 0.025% $ 20.0k | |
| Independent Director | 2.1yrs | US$167.44k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$181.44k | 0% $ 0 |
4.8yrs
Genomsnittlig anställningstid
62yo
Genomsnittlig ålder
Erfaren styrelse: GOSS s styrelse anses vara erfaren ( 4.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 14:20 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Gossamer Bio, Inc. bevakas av 22 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Carter Gould | Barclays |
| Eliana Merle | Barclays |
| Zhilin Long | Berenberg |